SCHEMBL5757499

SCHEMBL5757499

CCCCCSc1nc2ccc(S(=O)(=O)N[C@H](Cc3ccccc3)C(=O)NO)cc2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.50
MMP9 P14780 3/20 0.50
PPARA Q07869 5/20 0.46
PPARG P37231 4/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 3/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PPARD Q03181 2/20 0.42
ITGB3 P05106 1/20 0.42
ITGAV P06756 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
POLB P06746 1/20 0.42
TP53 P04637 1/20 0.42
MMP3 P08254 2/20 0.42
MMP14 P50281 2/20 0.42
MMP10 P09238 1/20 0.42
MMP12 P39900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5754992 0.99 MMP2 (0.49) MMP2MMP9PPARAPPARGMEN1
SCHEMBL5757695 0.92 POLB (0.51) MMP2MMP9PPARAPPARGMEN1
SCHEMBL5755029 0.92 MMP2 (0.52) MMP2MMP9PPARAPPARGMEN1
SCHEMBL5753452 0.92 PPARG (0.51) MMP2MMP9PPARAPPARGMEN1
SCHEMBL5756604 0.91 PPARA (0.48) PPARAPPARGMEN1CYP2C9KMT2A
SCHEMBL5754752 0.91 MMP2 (0.49) MMP2MMP9PPARAPPARGMAPT
SCHEMBL5757436 0.91 MMP2 (0.47) MMP2MMP9PPARAPPARGMAPT
SCHEMBL5755906 0.90 PPARA (0.48) PPARAPPARGMEN1CYP2C9KMT2A
SCHEMBL5754062 0.88 MEN1 (0.55) PPARAPPARGMEN1CYP2C9KMT2A
SCHEMBL5756783 0.88 MEN1 (0.45) PPARAPPARGMEN1CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 MMP2 8/4885MMP9 1/4885PPARA 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.